Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 29:15:1308296.
doi: 10.3389/fneur.2024.1308296. eCollection 2024.

The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review

Claudia Dosi  1 , Riccardo Masson  1
Affiliations

The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review

Claudia Dosi et al. Front Neurol. .

Abstract

Objective: To review the clinical characteristics and effect of treatment in patients with spinal muscular atrophy (SMA) and three copies of the SMN2 gene.

Methods: We conducted a literature search in October 2022 to identify English-language clinical research on SMA that included SMN2 copy number according to PRISMA guidelines.

Results: Our search identified 44 studies examining the impact of three SMN2 copies on clinical characteristics (21 on phenotype, 13 on natural history, and 15 on functional status and other signs/symptoms). In children with type I SMA or presymptomatic infants with an SMN1 deletion, three SMN2 copies was associated with later symptom onset, slower decline in motor function and longer survival compared with two SMN2 copies. In patients with SMA type II or III, three SMN2 copies is associated with earlier symptom onset, loss of ambulation, and ventilator dependence compared with four SMN2 copies. Eleven studies examined treatment effects with nusinersen (nine studies), onasemnogene abeparvovec (one study), and a range of treatments (one study) in patients with three SMN2 copies. In presymptomatic infants, early treatment delayed the onset of symptoms and maintained motor function in those with three SMN2 copies. The impact of copy number on treatment response in symptomatic patients is still unclear.

Conclusion: SMN2 copy number is strongly correlated with SMA phenotype in patients with SMN1 deletion, while no correlation was found in patients with an SMN1 mutation. Patients with three SMN2 copies show a highly variable clinical phenotype. Early initiation of treatment is highly effective in presymptomatic patients with three SMN2 copies.

Keywords: SMN2 gene copy; nusinersen; onasemnogene abeparvovec; prognosis; spinal muscular atrophy.

PubMed Disclaimer

Conflict of interest statement

The authors report personal fees from Biogen S.R.L., Roche, Avexis, and Novartis Gene Therapies outside the submitted work. The reviewer SD declared a shared parent affiliation with the authors to the handling editor at the time of review.

Figures

Figure 1
Figure 1
Search results and inclusion of studies. SMA, spinal muscular atrophy; SMN, survival motor neuron.
Figure 2
Figure 2
The proportion of ambulatory patients in cohort studies, stratified by SMN2 copy number (17, 23, 39, 55). The study by Ar Rochmah et al. grouped patients into those with one or two SMN2 copies compared with three or four SMN2 copies (39).
See this image and copyright information in PMC

References

    1. Aragon-Gawinska K, Mouraux C, Dangouloff T, Servais L. Spinal muscular atrophy treatment in patients identified by Newborn screening-a systematic review. Genes. (2023) 14:1377. doi: 10.3390/genes14071377, PMID: - DOI - PMC - PubMed
    1. CureSMA . State of SMA 2022 Report (2023). Available at: https://www.curesma.org/wp-content/uploads/2023/06/9062023_State-of-SMA_...
    1. Prior TW, Leach ME, Finanger E. Spinal muscular atrophy In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, LJH B, et al., editors. GeneReviews®. Seattle (WA): University of Washington; (2000) - PubMed
    1. Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics. (2015) 12:290–302. doi: 10.1007/s13311-014-0314-x, PMID: - DOI - PMC - PubMed
    1. Cuscó I, Bernal S, Blasco-Pérez L, Calucho M, Alias L, Fuentes-Prior P, et al. . Practical guidelines to manage discordant situations of SMN2 copy number in patients with spinal muscular atrophy. Neurol Genet. (2020) 6:e530. doi: 10.1212/nxg.0000000000000530, PMID: - DOI - PMC - PubMed

Publication types

LinkOut - more resources